<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165031</url>
  </required_header>
  <id_info>
    <org_study_id>17501</org_study_id>
    <secondary_id>J2K-MC-JZKA</secondary_id>
    <secondary_id>2019-003070-53</secondary_id>
    <nct_id>NCT04165031</nct_id>
  </id_info>
  <brief_title>A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation</brief_title>
  <official_title>A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug LY3499446 is safe and effective in&#xD;
      participants with solid tumors with KRAS G12C mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to an unexpected toxicity finding.&#xD;
  </why_stopped>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number or Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (21 Day Cycle)</time_frame>
    <description>Phase 1: Number or Participants with DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) (CRC Cohorts and Other Tumors Cohort)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 24 Months)</time_frame>
    <description>Phase 2: ORR: Percentage of Participants Who Achieve CR or PR (CRC Cohorts and Other Tumors Cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Progression-Free Survival (PFS) (NSCLC Cohorts)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 24 Months)</time_frame>
    <description>Phase 2: PFS (NSCLC Cohorts)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Average Concentration at Steady State of LY3499446</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles)</time_frame>
    <description>PK: Average Concentration at Steady State of LY3499446</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Average Concentration at Steady State of LY3499446 in Combination with Abemaciclib</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles)</time_frame>
    <description>PK: Average Concentration at Steady State of LY3499446 in Combination with Abemaciclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Average Concentration at Steady State of LY3499446 in Combination with Cetuximab</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles)</time_frame>
    <description>PK: Average Concentration at Steady State of LY3499446 in Combination with Cetuximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Average Concentration at Steady State of LY3499446 in Combination with Erlotinib</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles)</time_frame>
    <description>PK: Average Concentration at Steady State of LY3499446 in Combination with Erlotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: ORR: Percentage of Participants Who Achieve CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 24 Months)</time_frame>
    <description>Phase 1: ORR: Percentage of Participants Who Achieve CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: PFS</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 24 Months)</time_frame>
    <description>Phase 1: PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and SD</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 24 Months)</time_frame>
    <description>Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and SD</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LY3499446 Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 monotherapy orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 + Abemaciclib Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 and abemaciclib orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 + Cetuximab Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 orally and cetuximab intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 + Erlotinib Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 and erlotinib orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 monotherapy orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 + Abemaciclib Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 and abemaciclib orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 + Erlotinib Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 and erlotinib orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3499446 + Cetuximab Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given LY3499446 orally and cetuximab IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel Phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants given docetaxel IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3499446</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3499446 + Abemaciclib Phase 1</arm_group_label>
    <arm_group_label>LY3499446 + Abemaciclib Phase 2</arm_group_label>
    <arm_group_label>LY3499446 + Cetuximab Phase 1</arm_group_label>
    <arm_group_label>LY3499446 + Cetuximab Phase 2</arm_group_label>
    <arm_group_label>LY3499446 + Erlotinib Phase 1</arm_group_label>
    <arm_group_label>LY3499446 + Erlotinib Phase 2</arm_group_label>
    <arm_group_label>LY3499446 Phase 1</arm_group_label>
    <arm_group_label>LY3499446 Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3499446 + Abemaciclib Phase 1</arm_group_label>
    <arm_group_label>LY3499446 + Abemaciclib Phase 2</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3499446 + Cetuximab Phase 1</arm_group_label>
    <arm_group_label>LY3499446 + Cetuximab Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3499446 + Erlotinib Phase 1</arm_group_label>
    <arm_group_label>LY3499446 + Erlotinib Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Docetaxel Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have diagnosis of a solid tumor with KRAS G12C mutation that did not&#xD;
             respond to at least 1 line of standard therapy and has spread to other part(s) of the&#xD;
             body&#xD;
&#xD;
          -  For phase II, participants must be willing to have new tumor tissue biopsies (doctor&#xD;
             removes a small amount of tissue) during the study if it does not cause undue risks to&#xD;
             health&#xD;
&#xD;
          -  Participants must be willing to use highly effective birth control&#xD;
&#xD;
          -  Participants must have adequate organ function&#xD;
&#xD;
          -  Participants must be able to swallow capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have certain infections such as hepatitis or tuberculosis or HIV&#xD;
             that is not well controlled&#xD;
&#xD;
          -  Participants must not have another serious medical condition including a serious heart&#xD;
             condition, such as congestive heart failure, unstable angina pectoris, or heart attack&#xD;
             within the last three months&#xD;
&#xD;
          -  Participants must not have cancer of the central nervous system that is not stable&#xD;
&#xD;
          -  Participants must not be pregnant or breastfeeding&#xD;
&#xD;
          -  Participants must not use herbal supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Univ Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JZKA#?postal=</url>
    <description>A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>October 27, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

